Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Total Current Liabilities: 2020-2024

Historic Total Current Liabilities for Foghorn Therapeutics (FHTX) over the last 5 years, with Dec 2024 value amounting to $67.0 million.

  • Foghorn Therapeutics' Total Current Liabilities rose 49.74% to $85.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $85.1 million, marking a year-over-year increase of 49.74%. This contributed to the annual value of $67.0 million for FY2024, which is 14.64% up from last year.
  • Latest data reveals that Foghorn Therapeutics reported Total Current Liabilities of $67.0 million as of FY2024, which was up 14.64% from $58.4 million recorded in FY2023.
  • Foghorn Therapeutics' 5-year Total Current Liabilities high stood at $67.0 million for FY2024, and its period low was $18.8 million during FY2020.
  • In the last 3 years, Foghorn Therapeutics' Total Current Liabilities had a median value of $58.4 million in 2023 and averaged $60.2 million.
  • Data for Foghorn Therapeutics' Total Current Liabilities shows a peak YoY skyrocketed of 158.37% (in 2021) over the last 5 years.
  • Foghorn Therapeutics' Total Current Liabilities (Yearly) stood at $18.8 million in 2020, then soared by 158.37% to $48.7 million in 2021, then grew by 13.38% to $55.2 million in 2022, then increased by 5.85% to $58.4 million in 2023, then increased by 14.64% to $67.0 million in 2024.